Optimizing patient-reported outcomes for sarcoidosis
Patients with sarcoidosis can present with a wide range of symptoms that impact their quality of life (QoL). QoL represents one of the most important treatment priorities for patients. Therefore, measuring what matters to patients is of great importance, though it can be challenging due to the diverse presentation of the disease. Patient-reported outcome measures (PROMs) are designed to assess patients' subjective symptoms and their impact on their lives. Over the past decade, PROMS have been increasingly used in clinical trials and daily practice. In this review, we will provide an overview of frequently used generic- and disease-specific PROMS in the field op sarcoidosis. We summarize their psychometric properties and discuss limitations and future opportunities.
Authors
- Vivienne Kahlmann (ORCID: https://orcid.org/0000-0001-6003-7380)
- Donald Simon
- Catharina C. Moor (ORCID: https://orcid.org/0000-0002-5295-2877)
- Marlies S Wijsenbeek
Institutions
- South African Medical Research Council (ZA)
- Erasmus MC (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Current Opinion in Immunology
- Published
- 2026-01-14
- DOI
- https://doi.org/10.1016/j.coi.2025.102720
- Primary Topic
- Sarcoidosis and Beryllium Toxicity Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00